Combination vaccines with serogroup b meningococcus and d/t/p
Abstract
Serogroup B meningococcus antigens can successfully be combined with diphtheria, tetanus and pertussis toxoids (“DTP”) to provide effective combination vaccines for protecting against multiple pathogens. These combinations are effective with a range of different adjuvants, and with both pediatric-type and booster-type DTP ratios. The adjuvant can improve the immune response which the composition elicits; alternatively, by including an adjuvant it is possible for the compositions to have a relatively lower amount of antigen while nevertheless having immunogenicity which is comparable to unadjuvanted combination vaccines.
Claims
exact text as granted — not AI-modifiedWe claim:
1 : An immunogenic composition, comprising: (a) a serogroup B meningococcus immunogen; and (b) a diphtheria toxoid, a tetanus toxoid, and a pertussis toxoid, wherein the diphtheria toxoid is present in an excess relative to tetanus toxoid as measured in Lf units.
2 : The composition of claim 1 , further comprising an adjuvant.Join the waitlist — get patent alerts
Track US2017100472A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.